# A Phase 1b Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of JNJ-64565111 in Participants With Type 2 Diabetes Mellitus

> **NCT03235219** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 39 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** JNJ-64565111
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03235219
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-01
- **Primary completion:** 2018-02-19
- **Final completion:** 2018-02-19
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2025-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03235219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03235219, "A Phase 1b Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of JNJ-64565111 in Participants With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03235219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*